Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
GBA3 Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9H227 |
|---|---|
| Clone Names | 100311238 |
| Gene ID | 57733 |
|---|---|
| Other Names | Cytosolic beta-glucosidase, Cytosolic beta-glucosidase-like protein 1, GBA3, CBG, CBGL1 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | GBA3 (HGNC:19069) |
|---|---|
| Synonyms | CBG, CBGL1 |
| Function | Neutral cytosolic beta-glycosidase with a broad substrate specificity that could play a role in the catabolism of glycosylceramides (PubMed:11389701, PubMed:11784319, PubMed:20728381, PubMed:26724485, PubMed:17595169, PubMed:33361282). Has a significant glucosylceramidase activity in vitro (PubMed:26724485, PubMed:17595169). However, that activity is relatively low and its significance in vivo is not clear (PubMed:26724485, PubMed:17595169, PubMed:20728381). Hydrolyzes galactosylceramides/GalCers, glucosylsphingosines/GlcSphs and galactosylsphingosines/GalSphs (PubMed:17595169). However, the in vivo relevance of these activities is unclear (PubMed:17595169). It can also hydrolyze a broad variety of dietary glycosides including phytoestrogens, flavonols, flavones, flavanones and cyanogens in vitro and could therefore play a role in the metabolism of xenobiotics (PubMed:11784319). Possesses transxylosylase activity in vitro using xylosylated ceramides/XylCers (such as beta-D-xylosyl-(1<->1')-N-acylsphing-4-enine) as xylosyl donors and cholesterol as acceptor (PubMed:33361282). Could also play a role in the catabolism of cytosolic sialyl free N-glycans (PubMed:26193330). |
| Cellular Location | Cytoplasm, cytosol |
| Tissue Location | Present in small intestine (at protein level). Expressed in liver, small intestine, colon, spleen and kidney. Down- regulated in renal cell carcinomas and hepatocellular carcinomas |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
GBA3, or cytosolic beta-glucosidase (EC 3.2.1.21), is apredominantly liver enzyme that efficiently hydrolyzesbeta-D-glucoside and beta-D-galactoside, but not any knownphysiologic beta-glycoside, suggesting that it may be involved indetoxification of plant glycosides (de Graaf et al., 2001 [PubMed11389701]). GBA3 also has significant neutral glycosylceramidaseactivity (EC 3.2.1.62), suggesting that it may be involved in anonlysosomal catabolic pathway of glucosylceramide metabolism(Hayashi et al., 2007 [PubMed 17595169]).
References
Dekker, N., et al. Blood Cells Mol. Dis. (2010) In press :Noguchi, J., et al. Biochem. Biophys. Res. Commun. 374(3):549-552(2008)Hayashi, Y., et al. J. Biol. Chem. 282(42):30889-30900(2007)Tribolo, S., et al. J. Mol. Biol. 370(5):964-975(2007)Beutler, E., et al. J. Lab. Clin. Med. 144(2):65-68(2004)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
